Cara Therapeutics Stock Price and Value Analysis

Cara Therapeutics (NasdaqGM:CARA) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Cara Therapeutics to reach your target.

Target type

CARA Free Cash Flow Trend

Free Cash Flow trendline for CARA
Free Cash Flow trendline for Cara Therapeutics

Hmm, we can't give any reliable projection for Cara Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
None.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the CARA Numbers

CARA Price
(Cara Therapeutics stock price per share)
$0.00
[?] PE Ratio versus Sector 211% higher than other Healthcare stocks
[?] PE Ratio versus Industry 9% higher than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 77%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 1 fiscal years from 2012 to 2025 with positive net income, operating cash flow totaled -$5.5 million against net income of $8.4 million, or -0.65 times. Net income was negative in 13 of the 14 years, and those years are left out of the ratio.

In 2025, net income was -$18.2 million and operating cash flow was -$23.5 million, so no ratio is shown for that year.

In 2013, capital expenditures were $0 million, 0.2% of operating cash flow of $2.8 million, which leaves an estimated $2.8 million after capex. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2012 -6.3 -6 not reported n/a
2013 -4 2.8 0 n/a
2014 -17.7 -17.6 0 n/a
2015 -24.7 -21.5 0 n/a
2016 -57.3 -47.4 0.7 n/a
2017 -58.1 -54.8 0.1 n/a
2018 -74 -22.3 0.1 n/a
2019 -106 -109 0 n/a
2020 8.4 -5.5 0.3 -0.65
2021 -88.4 -60.1 0 n/a
2022 -85.5 -78.7 0 n/a
2023 -119 -92.1 2.4 n/a
2024 -29.4 -18.3 1 n/a
2025 -18.2 -23.5 not reported n/a

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $1.2 million in 2012 and $7.1 million in 2024, a compound annual growth rate of 16.1% over 12 years.

Revenue fell 66.0% from 2023 to 2024.

Our estimated free cash flow was -$19.1 million in 2024, a negative margin of 267.3% of revenue, meaning the estimate was below zero. In 2012 the estimated margin was negative 506.8%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2012 1.2 -6 -506.8%
2013 12 2.8 23.6%
2014 3.2 -17.7 -555.8%
2015 3.8 -21.5 -565.2%
2016 0.1 -47.5 -55276.5%
2017 0.9 -55 -6036.8%
2018 13.5 -22.5 -166.9%
2019 19.9 -109 -550.1%
2020 135 -5.7 -4.2%
2021 23 -60.2 -261.4%
2022 41.9 -78.8 -188.3%
2023 21 -92.6 -441.8%
2024 7.1 -19.1 -267.3%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $20.7 million against total liabilities of $11.1 million, or 186.3% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 34.7% of total assets in 2025, compared with 7.6% in 2014, an increase of 27.1 percentage points.

Stockholders equity was $20.9 million in 2025, up from negative equity of -$54.1 million in 2013.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2013 18.1 12.4 n/a -54.1
2014 55.9 52.7 4.3 51.7
2015 111 15.1 5.9 105
2016 63.8 12.1 13.1 50.7
2017 97 9.4 10.2 86.8
2018 191 15.1 57.2 134
2019 233 18.3 46.2 187
2020 271 31.7 22.2 249
2021 247 13.5 19.5 228
2022 182 63.7 23.5 159
2023 126 51.8 188 -62.1
2024 35.2 31.6 126 -91.1
2025 32.1 20.7 11.1 20.9

Price Versus Our Estimated Value

Positive free cash flow appears in 1 of the 14 fiscal years we hold for Cara Therapeutics from its current SEC filer.

We do not estimate a fair value for Cara Therapeutics while its free cash flow growth is not positive, so there is no value comparison here.

Year-to-year variability in free cash flow is volatile, measured at 77%.

We do not have a dividend yield for Cara Therapeutics.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 211% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 9% above the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Cara Therapeutics, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Cara Therapeutics (CARA) - - - - -
Abbott Laboratories (ABT) 178,390 38.4 2.4% 1.9% 49% above
Alkermes plc (ALKS) 7,552 - - 1.5% 315% above
Amphastar Pharmaceuticals (AMPH) 1,205 13.0 - 0.9% 98% above
ANI Pharmaceuticals (ANIP) 1,558 13.9 - - 188% above
Bristol-Myers Squibb Company (BMY) 120,192 13.0 4.3% 1.2% 85% above
Collegium Pharmaceutical (COLL) 768 22.7 - - 155% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1346830.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 13 of the 14 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: CARA annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in CARA

Does Cara Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: CARA

This example shows how we apply the Trendshare checklist to CARA: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 0.00
    • Market cap: —
    • EPS: —
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.